Contra-indicated in patients with impaired pulmonary function or paralytic ileus. Should not be used in patients currently using or within 14 days of using a monoamine oxidase inhibitor.
- TRADE NAMES: Nucynta (Janssen); Nucynta ER (Janssen); Palexia (Grunenthal)
- INDICATIONS: Immediate release formulation: moderate to severe acute pain; extended release formulation: moderate to severe chronic pain and neuropathic pain associated with diabetic peripheral neuropathy when a continuous analgesic is needed for an extended period of time
- CLASS: opiate
- HALF-LIFE: 5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Alvimopan, Amphetamines, Anesthestics, Anitemetics, Anticholinergics, Buprenorphine, Butorphanol, CNS depressants, Desmopressin, Droperidol, Hypnotics, Linezolid, MAO inhibitors, Mirtazapine, Nalbuphine, PEG-Interferon, Pegvisomant, Pentazocine, Phenothiazines, Sedatives, Sibutramine, SNRIs, SSRIs, St John's Wort, Succinylcholine, Thiazide diuretics, Tramadol, Tranquilizers, Trazodone, Tricyclic antidepressants, Triptans
- See adverse reactions attributed to class:
For extended release oral tablets: ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, ACCIDENTAL EXPOSURE, and INTERACTION WITH ALCOHOL
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 05/01/2026
